NASDAQ:INFI Infinity Pharmaceuticals (INFI) Stock Forecast, Price & News $0.19 +0.01 (+5.64%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$0.18▼$0.1950-Day Range$0.14▼$0.2052-Week Range$0.12▼$1.76Volume245,459 shsAverage Volume873,321 shsMarket Capitalization$16.85 millionP/E RatioN/ADividend YieldN/APrice Target$1.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Infinity Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside700.4% Upside$1.50 Price TargetShort InterestHealthy0.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.45 out of 5 starsMedical Sector901st out of 981 stocksPharmaceutical Preparations Industry429th out of 464 stocks 3.0 Analyst's Opinion Consensus RatingInfinity Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.50, Infinity Pharmaceuticals has a forecasted upside of 700.4% from its current price of $0.19.Amount of Analyst CoverageInfinity Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.71% of the float of Infinity Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInfinity Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Infinity Pharmaceuticals has recently increased by 7.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInfinity Pharmaceuticals does not currently pay a dividend.Dividend GrowthInfinity Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INFI. Previous Next 1.1 News and Social Media Coverage News SentimentInfinity Pharmaceuticals has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Infinity Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Infinity Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.81% of the stock of Infinity Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 34.61% of the stock of Infinity Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Infinity Pharmaceuticals are expected to decrease in the coming year, from ($0.46) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Infinity Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Infinity Pharmaceuticals is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Infinity Pharmaceuticals (NASDAQ:INFI) StockInfinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.Read More Receive INFI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INFI Stock News HeadlinesJune 2, 2023 | msn.comBoost for Abu Dhabi’s industrial sector as eight new projects announced at Make it in the Emirates ForumJune 1, 2023 | msn.com8 new projects announced at 'Make it in the Emirates' to boost Abu Dhabi’s industrial sectorJune 7, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!June 1, 2023 | finance.yahoo.comMEI Pharma Board of Directors Rejects Unsolicited ProposalJune 1, 2023 | marketwatch.comMEI Pharma Rejects Buyout Bid From Anson, Cable CarMay 31, 2023 | americanbankingnews.comInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Short Interest Up 7.5% in MayMay 31, 2023 | americanbankingnews.comInfinity Pharmaceuticals (NASDAQ:INFI) Receives New Coverage from Analysts at StockNews.comMay 30, 2023 | marketwatch.comMEI Pharma Up After Hours on Buyout Proposal From Anson, Cable CarJune 7, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 23, 2023 | americanbankingnews.comInfinity Pharmaceuticals (NASDAQ:INFI) Coverage Initiated by Analysts at StockNews.comMay 16, 2023 | marketwatch.comApoptosis Market Competitive Landscape: 2023-2031May 16, 2023 | americanbankingnews.comInfinity Pharmaceuticals (NASDAQ:INFI) Now Covered by StockNews.comMay 8, 2023 | americanbankingnews.comInfinity Pharmaceuticals (NASDAQ:INFI) Now Covered by Analysts at StockNews.comApril 30, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Infinity Pharmaceuticals (NASDAQ:INFI)April 29, 2023 | seekingalpha.comINFI Infinity Pharmaceuticals, Inc.April 27, 2023 | marketwatch.comPet Pharmaceuticals Market Analysis of Upstream Raw Materials, Downstream Demand and Current Dynamics 2023-2030 Zoetis, Boehringer Ingelheim, MerckApril 18, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds CVT, XM, INFI, and WAYN Shareholders About Its Ongoing InvestigationsApril 13, 2023 | finance.yahoo.comInfinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer ResearchApril 6, 2023 | marketwatch.comDiosgenin Market Hitting New Highs by 2030 | Sabinsa, Himachal Pharmaceuticals, Namiex Chemicals, Shanyang County Jinchuan Fengxing ChemicalApril 5, 2023 | americanbankingnews.comInfinity Pharmaceuticals (NASDAQ:INFI) Coverage Initiated at StockNews.comMarch 29, 2023 | marketwatch.comSpace Connectors Market Share, Size, Financial Summaries Analysis from 2023-2030 | Liaoning Koncepnutra, ChengDa PharmaCeuticalsMarch 29, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds INFI, INDT, MLVF, and SHBI Shareholders About Its Ongoing InvestigationsMarch 29, 2023 | marketwatch.com2023-2029 Chronic Lymphocytic Leukemia Drugs Market Size and Industrial Overview with Region Footprint | Latest Report by Absolute ReportsMarch 28, 2023 | finance.yahoo.comInfinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue EstimatesMarch 28, 2023 | finance.yahoo.comInfinity Pharmaceuticals Reports Full Year 2022 Financial ResultsMarch 28, 2023 | nasdaq.comWill Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should KnowMarch 27, 2023 | marketwatch.comCromolyn Sodium API Market Briefing 2023 to 2030 | Cambrex, LGM Pharma, JSN Chemicals, DEAFARMASee More Headlines INFI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INFI Company Calendar Last Earnings3/28/2023Today6/06/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INFI CUSIP45665G30 CIK1113148 Webwww.infi.com Phone(617) 453-1000Fax617-453-1001Employees23Year Founded2000Price Target and Rating Average Stock Price Forecast$1.50 High Stock Price Forecast$1.50 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+700.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,370,000.00 Net Margins-1,608.46% Pretax Margin-1,608.46% Return on Equity-956.26% Return on Assets-92.65% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio2.51 Sales & Book Value Annual Sales$2.59 million Price / Sales6.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-0.89Miscellaneous Outstanding Shares89,900,000Free Float81,085,000Market Cap$16.85 million OptionableOptionable Beta1.36 Social Links Key ExecutivesAdelene Q. PerkinsChairman, Chief Executive & Financial OfficerStéphane PelusoChief Scientific OfficerRobert IlariaChief Medical OfficerSeth A. TaskerSecretary, Chief Business Officer & Senior VPJennifer RobertsVice President-Clinical OperationsKey CompetitorsCatalyst BiosciencesNASDAQ:CBIOMolecular TemplatesNASDAQ:MTEMRegulus TherapeuticsNASDAQ:RGLSIndaptus TherapeuticsNASDAQ:INDPProcessa PharmaceuticalsNASDAQ:PCSAView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPSold 11,500 shares on 5/16/2023Ownership: 0.000%Wittenberg Investment Management Inc.Bought 172,000 shares on 5/15/2023Ownership: 0.191%BlackRock Inc.Sold 123,894 shares on 5/12/2023Ownership: 1.634%Renaissance Technologies LLCSold 184,600 shares on 5/12/2023Ownership: 0.263%Virtu Financial LLCBought 109,992 shares on 5/1/2023Ownership: 0.197%View All Institutional Transactions INFI Stock - Frequently Asked Questions Should I buy or sell Infinity Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares. View INFI analyst ratings or view top-rated stocks. What is Infinity Pharmaceuticals' stock price forecast for 2023? 2 brokerages have issued twelve-month price objectives for Infinity Pharmaceuticals' stock. Their INFI share price forecasts range from $1.50 to $1.50. On average, they expect the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 700.4% from the stock's current price. View analysts price targets for INFI or view top-rated stocks among Wall Street analysts. How have INFI shares performed in 2023? Infinity Pharmaceuticals' stock was trading at $0.5550 at the beginning of the year. Since then, INFI shares have decreased by 66.2% and is now trading at $0.1874. View the best growth stocks for 2023 here. Are investors shorting Infinity Pharmaceuticals? Infinity Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 619,800 shares, an increase of 7.5% from the April 30th total of 576,700 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is presently 0.5 days. Currently, 0.7% of the shares of the company are sold short. View Infinity Pharmaceuticals' Short Interest. When is Infinity Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our INFI earnings forecast. How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The biotechnology company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $11.88 million. Infinity Pharmaceuticals had a negative trailing twelve-month return on equity of 956.26% and a negative net margin of 1,608.46%. What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO? 10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX). What is Infinity Pharmaceuticals' stock symbol? Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI." Who are Infinity Pharmaceuticals' major shareholders? Infinity Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.63%), Renaissance Technologies LLC (0.26%), Virtu Financial LLC (0.20%), Wittenberg Investment Management Inc. (0.19%) and Susquehanna International Group LLP (0.00%). View institutional ownership trends. How do I buy shares of Infinity Pharmaceuticals? Shares of INFI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Infinity Pharmaceuticals' stock price today? One share of INFI stock can currently be purchased for approximately $0.19. How much money does Infinity Pharmaceuticals make? Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $16.85 million and generates $2.59 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. How can I contact Infinity Pharmaceuticals? Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for the company is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001. This page (NASDAQ:INFI) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Infinity Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.